"Rival Obesity Drugs Show Promising Results in Liver Disease Trials"
TL;DR Summary
Zealand Pharma's stock surged 32% after positive trial results for its weight-loss drug, survodutide, which also showed efficacy in treating liver inflammation caused by excess fat cells. The drug has received fast-track designation from the FDA and is undergoing five Phase-3 trials for people who are overweight or obese, positioning the company as a key player in the highly lucrative obesity therapeutics market alongside competitors like Novo Nordisk and Eli Lilly.
Topics:business#eli-lilly#healthcare-and-pharmaceuticals#novo-nordisk#obesity-market#weight-loss-drug#zealand-pharma
- Novo Nordisk and Eli Lilly rival soars 32% after promising weight-loss drug results CNBC
- Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis Yahoo Finance
- With competition flaring, obesity drug hits goal in liver disease study STAT
- Can GLP-1 Agonists Reduce Risk for Severe Liver Disease? Medscape
- Zealand crowns STOXX after liver disease drug trial data XM
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
2 min
vs 3 min read
Condensed
82%
402 → 71 words
Want the full story? Read the original article
Read on CNBC